TY - JOUR
T1 - Coronavirus Disease 2019 Outcomes, Patient Vaccination Status, and Cancer-Related Delays During the Omicron Wave
T2 - A Brief Report From the TERAVOLT Analysis
AU - TERAVOLT study group
AU - Bestvina, Christine M.
AU - Whisenant, Jennifer G.
AU - Torri, Valter
AU - Cortellini, Alessio
AU - Wakelee, Heather
AU - Peters, Solange
AU - Roca, Elisa
AU - De Toma, Alessandro
AU - Hirsch, Fred R.
AU - Mamdani, Hirva
AU - Halmos, Balazs
AU - Arrieta, Oscar
AU - Metivier, Anne Cecile
AU - Fidler, Mary J.
AU - Rogado, Jacobo
AU - Presley, Carolyn J.
AU - Mascaux, Celine
AU - Genova, Carlo
AU - Blaquier, Juan Bautista
AU - Addeo, Alfredo
AU - Finocchiaro, Giovanna
AU - Khan, Hina
AU - Mazieres, Julien
AU - Morgillo, Floriana
AU - Bar, Jair
AU - Aujayeb, Avinash
AU - Mountzios, Giannis
AU - Scotti, Vieri
AU - Grosso, Federica
AU - Geraedts, Erica
AU - Zhumagaliyeva, Ardak N.
AU - Horn, Leora
AU - Garassino, Marina Chiara
AU - Baena, Javier
N1 - Publisher Copyright:
© 2022 The Authors
PY - 2022/8
Y1 - 2022/8
N2 - Introduction: The Thoracic Centers International coronavirus disease 2019 (COVID-19) Collaboration (TERAVOLT) registry found approximately 30% mortality in patients with thoracic malignancies during the initial COVID-19 surges. Data from South Africa suggested a decrease in severity and mortality with the Omicron wave. Our objective was to assess mortality of patients with thoracic malignancies with the Omicron-predominant wave and evaluate efficacy of vaccination. Methods: A prospective, multicenter observational study was conducted. A total of 28 institutions contributed data from January 14, 2022, to February 4, 2022. Inclusion criteria were any thoracic cancer and a COVID-19 diagnosis on or after November 1, 2021. End points included mortality, hospitalization, symptomatic COVID-19 infection, asymptomatic COVID-19 infection, and delay in cancer therapy. Analysis was done through contingency tables and a multivariable logistic model. Results: We enrolled a total of 346 patients. Median age was 65 years, 52.3% were female, 74.2% were current or former smokers, 86% had NSCLC, 72% had stage IV at time of COVID-19 diagnosis, and 66% were receiving cancer therapy. Variant was unknown for 70%; for those known, Omicron represented 82%. Overall mortality was 3.2%. Using multivariate analysis, COVID-19 vaccination with booster compared with no vaccination had a protective effect on hospitalization or death (OR = 0.30, confidence interval: 0.15–0.57, p = 0.0003), whereas vaccination without booster did not (OR = 0.64, confidence interval: 0.33–1.24, p = 0.1864). Cancer care was delayed in 56.4% of the patients. Conclusions: TERAVOLT found reduced patient mortality with the most recent COVID-19 surge. COVID-19 vaccination with booster improved outcomes of hospitalization or death. Delays in cancer therapy remain an issue, which has the potential to worsen cancer-related mortality.
AB - Introduction: The Thoracic Centers International coronavirus disease 2019 (COVID-19) Collaboration (TERAVOLT) registry found approximately 30% mortality in patients with thoracic malignancies during the initial COVID-19 surges. Data from South Africa suggested a decrease in severity and mortality with the Omicron wave. Our objective was to assess mortality of patients with thoracic malignancies with the Omicron-predominant wave and evaluate efficacy of vaccination. Methods: A prospective, multicenter observational study was conducted. A total of 28 institutions contributed data from January 14, 2022, to February 4, 2022. Inclusion criteria were any thoracic cancer and a COVID-19 diagnosis on or after November 1, 2021. End points included mortality, hospitalization, symptomatic COVID-19 infection, asymptomatic COVID-19 infection, and delay in cancer therapy. Analysis was done through contingency tables and a multivariable logistic model. Results: We enrolled a total of 346 patients. Median age was 65 years, 52.3% were female, 74.2% were current or former smokers, 86% had NSCLC, 72% had stage IV at time of COVID-19 diagnosis, and 66% were receiving cancer therapy. Variant was unknown for 70%; for those known, Omicron represented 82%. Overall mortality was 3.2%. Using multivariate analysis, COVID-19 vaccination with booster compared with no vaccination had a protective effect on hospitalization or death (OR = 0.30, confidence interval: 0.15–0.57, p = 0.0003), whereas vaccination without booster did not (OR = 0.64, confidence interval: 0.33–1.24, p = 0.1864). Cancer care was delayed in 56.4% of the patients. Conclusions: TERAVOLT found reduced patient mortality with the most recent COVID-19 surge. COVID-19 vaccination with booster improved outcomes of hospitalization or death. Delays in cancer therapy remain an issue, which has the potential to worsen cancer-related mortality.
KW - COVID-19
KW - Cancer
KW - NSCLC
KW - Registry
KW - TERAVOLT
KW - Thoracic
UR - http://www.scopus.com/inward/record.url?scp=85134290270&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85134290270&partnerID=8YFLogxK
U2 - 10.1016/j.jtocrr.2022.100335
DO - 10.1016/j.jtocrr.2022.100335
M3 - Article
AN - SCOPUS:85134290270
SN - 2666-3643
VL - 3
JO - JTO Clinical and Research Reports
JF - JTO Clinical and Research Reports
IS - 8
M1 - 100335
ER -
